GNW-Adhoc: ADC Therapeutics again meets the standards for continued listing on the NYSE

^LAUSANNE, Switzerland, Jan. 05, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE:

ADCT) announced today that the Company will be acquired by the New York Stock Exchange on January 2, 2024

Stock Exchange (NYSE) has received notice that it has met the criteria for

a continued listing pursuant to Section 802.01C of the NYSE Listed

Company Manual complied again and therefore off the non-conforming list

issuers will be removed from the NYSE. The company previously had a statement

received from the NYSE that it meets the criteria for continued listing

not fulfilled because the average closing price of its common shares is above

was below USD 1.00 for a period of 30 consecutive trading days. There

the closing price of the common shares on December 29, 2023 and the average

Closing price of the common shares for the 30 trading day period ending on December 29th.

Ending December 2023, each was over $1.00, this has been resolved.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a global leader in commercial

Stage-active company and pioneer in the field of antibody drug development

Conjugates (AWK). The company is developing its proprietary AWK technology

further to develop the treatment paradigm for patients with hematological malignancies

and solid tumors.

ADC’s CD19-targeting ADC ZYNLONTA (loncastuximab-tesirine-lpyl).

Therapeutics received accelerated approval from the FDA and the

European Commission granted conditional approval for the treatment of the

relapsed or refractory diffuse large B-cell lymphoma after two

or more lines of systemic therapy. ZYNLONTA is also located in the

Development in combination with other active ingredients and in earlier

lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has several AWKs in the

ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland

through offices in London, the San Francisco Bay Area and New Jersey. For

For more information please visit https://adctherapeutics.com/

(https://www.adctherapeutics.com/) and follow the company on LinkedIn

(https://www.linkedin.com/company/adc-therapeutics/).

ZYNLONTA(®) is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Safe-

Harbor provisions of the Private Securities Litigation Reform Act of 1995. In

In some cases, you can identify forward-looking statements by terms such as “may”,

“will”, “should”, “would”, “expect”, “intend”, “plan”,

“anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”,

“aim”, “future”, “continue” or “appear” or negation

of these terms or similar expressions, although not all

forward-looking statements contain these identifying words.

Forward-looking statements are subject to certain risks and uncertainties,

which could cause actual results to differ materially

differ as described. Among the factors causing such deviations

can include, among other things: the actual ZYNLONTA(®) sales for the 4th

Quarter 2023, the success of the updated corporate strategy

Company, including operational efficiency, capital use and

portfolio prioritization, the company’s ability to mitigate the decline

To achieve total cost of ownership for 2023 and 2024, the expected cash runway

by the 4th quarter of 2025, the effectiveness of the new commercial

Market launch strategy, competition from new technologies and the

the Company’s ability to increase ZYNLONTA(®) sales in the United States; the

Capability of the Swedish Orphan Biovitrum AB (Sobi(®)), ZYNLONTA(®) im

to successfully market the European Economic Area, as well as the

market acceptance, appropriate cost reimbursement and future revenue

this product; the approval of the submitted by Overland ADCT BioPharma

BLA for ZYNLONTA(®) in China by the NMPA and future revenues therefrom

Capability of our strategic partners, including Mitsubishi Tanabe

Pharma Corporation, the regulatory approval for ZYNLONTA(®) in foreign countries

jurisdictions, as well as the timing and amount of future ones

income and payments to us from such partnerships; any

Impact of data reported by the University of Miami for its IIT in FL;

the schedule and results of the Company’s clinical trials or

its partners, including LOTIS 5 and 7, ADCT 601 and 602 as well as the

The Company’s early-stage pipeline research projects; Measures of the

FDA or foreign regulatory authorities with respect to the products or

the Company’s product candidates; projected income and expenses; the

Company indebtedness, including Healthcare Royalty Management

and Oaktree and Blue Owl facilities, and the restrictions imposed on the

Business activities of the company are imposed by these debts

Ability to repay this debt and the significant cash available to do so

servicing of this debt is necessary; and the ability of

corporate, financial and other resources for its research,

maintain development, clinical and commercial activities. More

Information about these and other factors that may cause the

actual results may differ materially from those reflected in the forward-looking statements

Expected differences can be found in the “Risk Factors” section in the annual report

of the Company on Form 20-F and other periodic reports and

The company’s filings with the Securities and Exchange Commission. This

Statements involve known and unknown risks, uncertainties and others

There are factors that could cause actual results to vary,

achievements, successes or prospects may differ significantly from future results,

Performances, successes or prospects differ in such

expressed or implied by any forward-looking statements. The

Company cautions investors not to rely on the information contained in this document

rely on forward-looking statements. The company is not

undertakes to revise or revise these forward-looking statements

update to reflect events or circumstances after the date hereof

press release unless required by law.

CONTACTS:

investor

Eugenia Litz

ADC Therapeutics

[email protected] (mailto:[email protected])

+44 7879 627205

+1 908-723-2350

media

Nicole Riley

ADC Therapeutics

[email protected] (mailto:[email protected])

+1 862-926-9040

°

ttn-28